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1. INTRODUCTION 
lnterleukin-6 (IL-6) is a cytokine whose wide variety 
leading to heterogeneity are: incomplete removal of in- 
itiator mcthioninc from the N-terminus [6], proteotytic 
truncation of tither the N- or C-terminus [7,8] and 
of biological functions uggests a central role in the host dcamidation [9,10] or oxidation [IO] of sensitive amino 
defense against infection and inflammation, Among the acid residues. Here we present an additional form of 
various activities originally described separately and modification leading to heterogeneity; the addition of 
later attributed to this single polypeptide arc the final 
differentiation of B-cells into IgG-secretin cells [ 11, 
amino acids to the C-terminus due to partial read- 
through of the termination codon. The variant, con- 
plasmacytoma nd B-cell hybridoma growth induction 
[2], and induction of acute-phase proteins in hcpato- 
cytes [3]. The mature murine IL-6 molecule is a 187 
amino acid polypeptide with two disulfide bridges. 
Human and murine lL-6 are 42% homologous at the 
amino acid level with highest homology restricted to the 
taining three additional amino acids (Gin-Lys-Leu) at 
the C-terminus, accounted for 50-6OVo f the total IL-6 
expressed and had activity equal to the wild-type in 
several different assays. As recent studies of IL-6 had 
demonstrated that the C-terminal tetrapeptide is ab- 
solutcly required for biological activity, the question of 
middle and the C-terminal regions [4,5]. Studies with 
deletion mutants have shown that the C-terminus of the 
polypeptide is critical for bioactivity of this cytokine 
[16,18]. In order to obtain sufficient amounts of pure 
murine IL-6 for structure elucidation and for studies 
with a mouse model of inflammation. we exnresscd the 
whether the C-terminal extension might have biological 
activity was of considerable interest. We found equi- 
valent biological activity and suggest that maintenance 
of an a-helical structure at the C-terminus is important 
for activity. 
L 
mature form of mIL-6 in E. coli. 
Proteins expressed in E. coli by recombinant DNA 
technology are occasionally found to contain structural 
modifications which lead to heterogeneity of the desired 
product. Some of the well recognized modifications 
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2, MATERMLS AND METHODS 
2.1, Cloning, expression and purificrrrion of mlL6 
The murine IL-6 gene was cloned from a cDNA library prepared 
from mouse 3774.1 monocyteknacrophage cells [I I]. An expression 
plasmid was constructed and used to transform E. co/i strain GE81 as 
described e&where [if]. Mature IL-6 was expressed at abeut 5-10% 
of total cell protein in an insoluble form and was identified on SDS- 
PAGE as a close doublet of bands both of which reacted with anti- 
murine and anti-human IL-6. The purification of the correctly ter- 
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3.3. P~~li& wtnflflrng twd rlcrcrnrinttrian uf rlrr C~l~rt~rirtrrx 
Sempirr wrc di~i~wti wgrlna~ 25 m?+i ammonium bicatbonaw, pl-t 
% tsvsrni&r~. EReh rempis wr6 matto 2 hi in ~nanidine hydwhioridc 
(C&Cl) rnd cndoprowina~e Gtn-6 in draw wu ~ridai IO yc~ II I:3 
rndu by wctgirl ot’Giu.C:ml L6 Ahrr I7 h, uddiltunni prnwimuo ~$1 
ad&d (1:50) owl the itwkxwlon canrtrrued I’AP 24 morb h. Aiiqu~~~ of 
the tligcltn IO bc sempnrcd bclarc and at‘rer reduetian wifh t3TT WCPC! 
firxr brau&iu IO 5 hl GnCl rbcn tmsted wilh cirhcr IO m?vi BTT (31 
wkr far 30 rnin 81 45JCq Pcplttte m:rpping rmil iavrialion wwc danc 
on a Cl8 revcrac plum ratrrnrn (Pep-RPC MR5I5, Pharnwia) in II 
grttdienr of nccronhriic wllh 0. I% TFA. Pep~iticw ia be nnnirxrd were 
brought i~lillOll 10 dryncw in a Sawni Stwd-Vnc prior Ici Naxmin~ii 
wqucncc ar amino acid campori~lan :mnlyrk 
2.4. 1axlSstl.v~ 
The BP ccit rtimutnlion n~aay was performal sccnrding IQ Anrdcrr 
El ni. [14). IL.6 wirily was alw mcawrcd by ilr nbiiiry ra srimulalc 
prodwion by primary lrrpatocy~c~ asprcriuuslr dcaribcd IIS), 
3. RESULTS 
3.1 . Purificatiott atrd it&id characterirarion of tttlL-6 
The mIL-6 was expressed in the insoluble fraction of 
the E. co/i cell lysate producing a closely spaced doublet 
at about 23000 Da on SDS-PAGE (Fig. lA, lane 4). 
Each of the forms was approximately equally repreWV 
sented in the doublet and both reacted with anti-IL-6 
antibody (Fig. lR, lane 4). 
= 
1 
., 
Fig. I, Exprcrsion of mlL.6 in E. ruli wnina. Taoi ceil lysarcs t’ram 
various cxpreraion rtmins wrr cvalumtl by (A) SDSPAGE [t3] nnd 
(U) Wesrcrn blat nnslyk. Lane I, GESlt’pBR322; 2, GEt9W 
pNBZl7; 3, Wl tWpND217; 4, GEZtl/pNB217; 5, M.W, standards. 
3.2” Verificcrtistr of disut/ide bond hottmpeticir_v 
In or&x to determine whether the two IL-G variants 
had different disulfide bonding patterns, the digested 
peptidcs were compared on peptidc maps with and 
without first treating the digest with 100 mM dithio- 
A washed inclusion body preparation (Fig. 2, lane 4) 
was prepared and was dissolved in 4 M GnCl at pH 
7,5-&O prior to chromatography on Sephacryl S-200. 
An IL-6 fraction was obtained which upon dialysis 
resuhed in a soluble, activemIL-6 preparation, Optimal 
refolding was from 25 mM Na acetate, pH 5.5 and at- 
tempts to refold from material solubilized with reduc- 
ing agents present or without the gel filtration step 
resulted in reduced recovery of IL-6. The IL-6 prepara- 
tion at this stage contained both forms of the protein 
(Fig. 2, lane 5). Two-dimensional gel electrophoresis of 
the preparation at this point revealed that the two forms 
had different isoelectric points as well as apparent 
molecular mass (data not shown). The form with the 
higher p1 (7.8) had the higher molecular mass while the 
species with lower pI 47.1) had the lower masL, 
In order to characterize further the two IL-6 forms, 
they were separated using cation exchange chroma- 
N-terminal sequencing of the separated IL-6 species 
verified that each had methionine at its N-terminus and 
amino acid analysis uggested no gross differences bet- 
ween the compositions of the two molecules. 
tsgraghy. Based upon elution order from a Bakerbond 
CBX column, they were designated CBXl and CBX2. 
Fig. 2. SDS-PAGE analysis of mIL-6 purification steps. Lane 1, 
molecular weight markers; 2, soluble fraction of E. co/i cell lysate; 3, 
insoluble pellet from E. colt’ (GESl) cell lysate; 4, washed inclusion 
body preparation; 5, rnIL-6 fraction frown Sephacryl S-200 
chromatography; 6, purified, correctly terminated mlL-6 peak from 
cation exchange chromatography (CBXl); 7, purified, extended C- 
terminal variant of mIL-6 peak from cation exchange ((33x2). 
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tlrrritsl (CRT) in the ptt?acnfe af 5 M CjinCl (Fig. 151, In wcrc idcntifkd by amino at&l nnalyrir and autamatod 
eneh CRWC~ two pcrptidcc clixappcnrrd from tha rhrcs- sxjrrencing to be the rrrplsftbc Grerrninal peptlda far 
mwtagrtim representing the unreduecd dlge?et and four CBXl and CBXZ Peprids 3 Pram the CBXi cli~c~r hwd 
new pepticha appeursd in each DTT feduccrd di@% the CcIrreCt C-carminwl J;cquencc far rnDk6, (FLW- 
&W af the twa pepriderr which diseppeared after teduca TLRSTRQT). Pcptide 4, recovered from the CBX2 
tion was identified by amino acid analyrir 8s pspridcrr digat, had the xequcrsco ~~~~~~~~~~~~~~~, 
76-84 and U-96, one 08 the diswlfide linked peptide revsaling three additional amino aeido at the C- 
pairs expected in mlL-6, l”hrt second expected dirutfide rrrmlnus of CBXZ, Inapeaion af the nuelcstidc ae- 
linked pcptide pnir wars not identifiecl, but identification quenecs in the p&mid at the 2’ end of’ mIL.4 eDNA 
of ane of the two eotrect pairs esmbinfd with the iden- suggrstod a mechanism far this; result. 
tieal change in pcptidr maps between the rcdueed and In the DNA sc@rence of TAO stop sadan and srn ada 
rrnreduced digests nuggeots that bath CBXL and CBX2 jaccn? Hir,dllt rite (AACKTT) were apparently rend 
hare the same, correct S-S bond partcrn, through resulting in B glwtarninrr (Q) insertion for the 
TACj corlon, and IyGnc (IQ, leucirIe CL) Car the 
2.3. Men f(fkwtiorr of C-tm~itirrl l~eteropmeity 
The gin-C: pcptide maps of CBXl and CBX2 rcvcnled 
only one unique pcpride for each form (Fig. 4); pcpticlc 
3 wtlo present in the CBXl peptide map but nbaent in 
the CBX2 map and pcptide 4 was prcscnt in the CBX2 
map but missing in the CBXl map. These two pcptidcs 
AAGC”T”T (Fig& 5). A TAA eedon following the 
HirldIII site ctluacd termination, Such 8 readthrough of 
R UAG cedon is ecmsirtcnt with an amber suppressor 
mutation in E, co/i strain CE81. in support of this 
hypothcsia, this plasmid results in the expression OP a 
single mIL-6 immunorcactivc band corresponding in 
size to unmodified mature IL-6 when transformed into 
GE196 and WC31 1Q (Fig, l), 
two other strains without the SUDRC~SSO~ mutation, 
I I I I 
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Fig. 3. Endoproteinase Glu-C peptidc maps of reduced and non- 
reduced digests. CRXZ(A) and CrSXl(Ej weic earli digested as 
described in Section 2, and aliquots compared before and after reduc- 
tion with DTT. Peptide IO was identified as peptide 70-84 disulfide 
linked to peptide 85-96 (numbered according to [4]), Pcptide 7 was 
not conclusively identified. The same four new peptides (arrows) ap- 
peared in each digest upon reduction with DTT. 
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rly. 4. Endoproteinase Glu-C peptide maps of CBXl and CBXZ. 
CBXI and CBXZ were digested and chromatographed as described in 
Materials and Methods. Peptides 3 and 4 (arrows) were identified as 
the C-terminal peptides respectively of CBXl and CBX2. 
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This novel mIL-6 variant with a C-terminat addition 
previcled us with the sppnrfunity to determine rhc eT- 
t&t of this structural modi~icatisn bn the bialogieal ac- 
tivity of this cytskinc. Reecntly, it has become clear that 
residues irr the C-terminal region inrluding those very 
clese to the Gtcrminus af human IL-6 are required for 
the activity or this cytokine [Iti-181, Antibodies which 
ncutralirr IL-6 mztivity bind an epitoge new the C- 
terminus [I71 and deletion mutants with as few as four 
f 6 
4 
of the C-terminal amino acids missing eompktcty fose 
activity [16j. The Imer finding suggests that the ex- 
trcmc C-rerminal residues are either directly involved in 
LInekgroufld 
_______-mm-----...c-- 
0 
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Fig. 6, Comparison of the bioacrivities of CBXl and (3x2 in the f39 
cdl stimulation assay. SO00 Bc) ceils mainmined in lscovc’s Modified 
Dulbecco’s Medium (IMDM), S% KS, SX IO- s M mercap- 
toethanol, penicillin and streptomycin (100 bl) were placed in 100 141 
of concentrations of IL-6, After 54 h, cells were labeled whh I 
&i/well [‘Hlthymidinc, Closed circles (J) rcprcscnr CDXI and closed 
squares (U) represent (33x2. One unh was the amount of IL-6 re- 
quired to induce 50% maximal stimulation. 
a function required for activity or that they arc 
necessary to maintain some structure required for a.0 
tivity. Bioassays comparing the native and C-terminally 
extended variant of mIL-6 revealed that the specific ac- 
tivity was unaffected by addition of the tripeptide, Gtn- 
Lys-Leu. The finding that this addition does not ntrer 
the biological activity of IL-G, argues that this 
modification has not caused isruption of the structure 
at the C-terminus nor the overall fold OF the protein and 
suggests that the charged C-terminal carboxyl is not 
directly involved in receptor binding. In addition, the 
bulk of the extra three amino acids, including a charged 
residue, must introduce neither steric nor electrostatic 
constraints on the ability of IL-6 to bind to its receptor. 
The IL-6 receptor belongs to a structurally homo- 
3,4. Activities of the native rend extended ML-6 
Two assays, based on different cell types, were used 
to evaluate the relative activities of the native and C- 
terminally extended forms of mIL-6. Using I39 hybri- 
doma cells, the specific activity of rmIL-6 in this assay 
ranged between 4.3 x IO’ and 2.8 x lo* units per milli- 
gram and was dependent upon the age of the B9 culture 
not the preparation of 12-6. In comparative assays 
(n =4), no significant difference was seen between the 
two forms. A representative assay is shown in Fig. 6. In 
the hepatocyte stimulating factor assay, the ability of 
IL-6 to specifically stimulate the production of 
fibrinogen by primary hepatocytes was measured and a 
specific activity of 1.2 x 10’ units/mg was found. Again 
in comparative assays (n = 4), no difference in activity 
was seen. 
logous family to cytokine receptors [ 19,201. The protein 
fold of the cytokine ligands for this receptor family is 
known [Zl] or predicted to be four helix bundles 
[19,22]. In a model of binding for these receptor-ligand 
pairs, Bazan 1221 has proposed that there is interaction 
of a recognition helix of the cytokine with a ‘rigid 
groove’ in the receptor. Mutation analysis of one of 
these ligands, human growth hormone (hGM), identi- 
fied residues on the face of the C-terminal helix, helix 
D, which form the primary receptor binding structure 
[23]. Alignment of conserved sequence patterns in helix 
D of helical cytokine structures with hGH, identified 
exposed residues in IL-6 which might be important in 
receptor binding [X2]. Of the four C-terminal residues 
of rat [24], murine [25] and human [1,5] IL-6 (X-Arg- 
Gin-X), arginine is conserved and aligns with one of 
these exposed residues. It might therefore be respon- 
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dble ['or the loss of  ae|ivity upon deletion or  the four C- 
terminal residues. A l ternat ively.  mainten~n~e o f  a com-  
plete re¢ol=nifion helix lneludinl~ all four C-terminal 
residue~ could  be the impor tant  requi rement  for func-  
(ion. Several  model:~ o f  secondary  ~trueture predict  an 
a-.helix at the C-terminu~ of [L-6 [16.191. The add i -  
t ional  residues, GIn-Lys-Leu, of  the fu l ly  active variant 
reported here are each amino acids found mo~l f ie.  
quently in the (r.helix [26] and therefore are unlikely to 
disrupt an important ~.helieal slrucmre a~ the C- 
ter minus, 
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